David C. Dvorak joins Mesentech's Board of Directors

David served as President and Chief Executive Officer of Zimmer Biomet (NYSE and SIX: ZBH) from 2007 to 2017. He joined the company as Senior Vice President and General Counsel in 2001 following the company’s spin-off from Bristol-Myers Squibb. During his 16-year tenure with Zimmer Biomet, the company was built into a Fortune 500 Company with revenues growing from $1.2 billion to $7.7 billion, employment expanding from 3,400 to 18,500 and market capitalization appreciating from $6.2 billion to $25.8 billion.

Before joining Zimmer, David served as Senior Vice President and General Counsel of STERIS Corporation (NYSE: STE). Earlier in his career, he practiced corporate law, focusing on mergers and acquisitions and on securities law. He holds a Bachelor of Science in Business Administration (Finance) from Miami University (OH) and a J.D., magna cum laude, from Case Western Reserve University School of Law, where he was elected to the Order of the Coif.

David served on the board of St. Jude Medical, Inc. (NYSE: STJ) prior to its sale to Abbott Corporation. Additionally, he served on the board of the medical device trade association AdvaMed from 2007 to 2017, including as Chairman from 2012 to 2014. He currently serves as Chairman of the Board and Chief Executive Officer of DeepThink Health and director of Mach Medical, LLC and the Orthpaedic Research and Education Foundation.